Olfactory outcomes in the management of aspirin exacerbated respiratory disease related chronic rhinosinusitis

Daniel B. Spielman*, Jonathan Overdevest, David A. Gudis

Department of Otolaryngology — Head and Neck Surgery, Columbia University Medical Center, New York, NY, 10032, USA

Received 23 May 2020; accepted 29 July 2020
Available online 26 August 2020

Abstract

Patients with aspirin exacerbated respiratory disease (AERD) experience a severe and recalcitrant form of chronic rhinosinusitis with nasal polypsis (CRSwNP) and asthma, which are exacerbated by aspirin/NSAID ingestion. As compared with aspirin-tolerant CRSwNP, patients with AERD experience more severe olfactory dysfunction, which is one of the key contributors to the observed decrease in quality of life (QOL) in this disease. The objective of this paper is to review the published olfactory outcomes observed with various treatment modalities.

Background

Aspirin exacerbated respiratory disease (AERD) is defined as chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma, which is acutely worsened by aspirin (ASA)/NSAID ingestion. This condition was initially described by Widal et al in 1922 and later coined Samter’s Triad after Samter and Beer’s publication in 1968.1,2 The true prevalence of AERD is difficult to ascertain, but is estimated to be 0.3%—0.9% of the population and 7% in patients with asthma.3

Copyright © 2020 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1  Studies presented.

| Intervention category | Source                        | Intervention | Study type | Population (n) | Olfactory outcome metric | Resultsa |
|------------------------|-------------------------------|--------------|------------|-----------------|--------------------------|----------|
| ESS                    | Mendelsohn et al7             | ESS          | Cohort     | 50              | Patient reported olfactory dysfunction: yes/no | Preop: 46/50 (92%) Postop: 28/47 (59%)b |
|                        | Young et al10                 | ESS          | Case series | 11              | Visual analog scale range: 0–10 | Preop: 9.32 ± 1.38 Postop 24 mo: 6.13 ± 4.33* Postop 36 mo: 8.00 ± 2.83* |
| ASA                    | Berges-Gimeno et al10         | ASA (650 mg Bid) | Cohort   | 126             | Patient reported olfactory dysfunction: interval scale 0–5 0 = complete anosmia 3 = partial smell, majority of time 5 = perfect, continuous sense of smell | Baseline: 0.0c Post ASA (6 mo.): 3.0* Post ASA (1 yr.): 3.0* |
|                        | Gudziol et al15               | ASA (300 mg daily) | Cohort   | AERD: 16 Control (CRSwNP): 15 | Sniffin’ Sticks TDI Score range: 1–48 Hyposmia <30 and ≥15 anosmia <15 | Baseline AERD: 19.16 ± 9.52 CRSwNP: 26.80 ± 10.25 Post ASA (7 mo.) AERD: 20.66 ± 9.29 CRSwNP: 26.02 ± 10.44 Baseline: 0.66 ± 1.06* Post ASA: 1.74 ± 1.65* |
|                        | Walters et al31               | ASA (40.5–1300 mg daily) | Case series | 92             | Patient reported olfactory dysfunction: interval scale 0–5 0 = complete anosmia 3 = partial smell, majority of time 5 = perfect, continuous sense of smell | Baseline → Post ASA (6 mo.) AERD-ASA: 10.0 → 6.3* AERD-placebo: 8.0 → 8.4 ATA - ASA: 8.2 → 8.0 ATA - placebo: 6.5 → 8.3 |
|                        | Świecaryńska-Krępka et al32    | ASA (624 mg daily) | Cohort; double blinded placebo controlled | AERD + ASA: 8 AERD + Placebo: 7 ATA + ASA: 5 ATA + placebo: 8 | Visual analog scale range: 0–10 | Baseline → Post ASA (6 mo.) AERD-ASA: 10.0 → 6.3* AERD-placebo: 8.0 → 8.4 ATA - ASA: 8.2 → 8.0 ATA - placebo: 6.5 → 8.3 |
|                        | Ibrahim et al32               | ASA (325–650 mg Bid) | Case series | 111            | Patient reported improvement in smell: yes/no | Post ASA improvement: 34/111 (30.6%) Change in score at follow-up Control: −0.1 Long term |
|                        | Sweet et al33                 | ASA 650 mg Bid (average) | Cohort   | AERD + Placebo (Control): 42 AERD + discontinued | Patient reported olfactory dysfunction: interval scale 1–5 1 = perfect smell | Baseline → Post ASA (6 mo.) AERD-ASA: 10.0 → 6.3* AERD-placebo: 8.0 → 8.4 ATA - ASA: 8.2 → 8.0 ATA - placebo: 6.5 → 8.3 |

aResults may vary depending on the specific study and methodology.
| Intervention category | Source | Intervention | Study type | Population (n) | Olfactory outcome metric | Results |
|-----------------------|--------|--------------|------------|----------------|-------------------------|---------|
| ASA: 30 AERD + ASA long term: 35 | Rozsasi et al | ASA 100 mg vs. ASA 300 mg | Cohort | ASA 100 mg: 7 ASA 300 mg: 7 | 5 = complete anosmia | ASA: −1.2* Short term ASA: −1.3* → +0.5 after d/c  
(12 mo. Post ASA Score - Baseline) 300 mg: −3* 100 mg: −1  
>50% reduction post Dupilumab at 4 mo.* (numerical data not published) | Olfactory improvement in 5/7 (71%) at 6 months** Baseline → Post Omalizumab (6 mo.) 8.67 ± 1.33 → 5.44 ± 2.62* Baseline → Post Omalizumab (12 mo.) 8.8 (4.6–10) → 3.0 (0.9–7.4)** Baseline → Post Mepolizumab (12 mo.) 4 → 3* |
| Dupilumab | Laidlaw et al | Monoclonal antibodies | Cohort; double blinded placebo controlled | Control (AERD): 11 Dupilumab: 8 | UPSIT + SNOT-22 Smell Subscore | |
| Omalizumab | Philips-Angles et al | Case series 7 | Visual analog scale range: 0–4 | | |
| Omalizumab | Tiotiu et al | Case Series 9 | Visual analog scale range: 0–10 | | |
| Omalizumab | Hayashi et al | Case Series 21 | Visual analog scale range: 0–10 | | |
| Mepolizumab | Tuttle et al | Case series 14 | SNOT-22 smell subscore range: 1–5 | | |
| ESS vs. ESS + ASA (500 mg daily) | Havel et al | Combination therapy | Cohort | ESS = 81 ESS + ASA = 65 | Patient reported olfactory dysfunction: interval scale 1–4  
1 = no symptoms daily 4 = severe symptoms daily | ESS Preop: 3.72 Postop (1 yr): 3.52 Long term (min 18 mo.): 3.55 ESS + ASA Preop: 3.80 Postop (1 yr): 2.56* Long term (min 18 mo.): 2.94* |
| ESS + ASA | Cho et al | Case Series 21 | SNOT-22 smell subscore range: 1–5 | | Baseline Preop: 4.1 ± 1.3 Postop (1 mo.): 1.2 ± 0.9* |

(continued on next page)
Patients with AERD experience an increase in upper and lower airway reactivity following exposure to Cox-1 inhibitors, i.e. ASA or nonsteroidal anti-inflammatory drugs (NSAIDs). Symptoms may manifest as early as 30 minutes after ingestion, with increased nasal congestion, rhinorrhea, shortness of breath, or wheezing. Extra-pulmonary cutaneous and gastrointestinal symptoms have also been documented in a subset of patients. Diagnosis is established with ASA challenge testing. Over time, patients develop nasal polyposis, nasal obstruction, and hyposmia. The sinonasal symptoms associated with AERD are often severe and prompt patients to seek intervention. As compared to their counterparts with ASA-tolerant chronic rhinosinusitis, patients with AERD tend to have recalcitrant disease, requiring more frequent and revision sinus surgery with higher rates of healthcare utilization.

![Image](https://via.placeholder.com/150)

**Table 1 (continued)**

| Intervention category | Source | Intervention | Study type | Population (n) | Olfactory outcome metric | Results
|-----------------------|--------|--------------|------------|-------------------|-------------------------|---------|
| Fruth et al⁴² | ESS + low dose ASA (100mg) vs. ESS + placebo | Cohort; Double Blinded Placebo | ESS + ASA: 18 ESS + placebo: 13 | Sniffin’ Sticks Odor Identification Range: 0–8 Score = mean sum of correctly identified items on each side | Post ASA (6 mo.): 1.9 ± 0.4 Post ASA (24 mo.): 1.4 ± 0.5 Difference (36 mo.): Postop Score = Preop Placebo: 0.2 ASA: 1.9 |

*p < .05.

ASA: aspirin desensitization therapy; TDI: threshold, discrimination, identification score; CRSwNP: chronic rhinosinusitis with nasal polyposis; SNOT-22: Sinonasal Outcome Test-22; ATA: aspirin tolerant asthma.

* Mean, unless otherwise noted.

* Statistical significance not reported.

* Median (interquartile range).

**Table 2** Summary of studies presented.

| Intervention | Numbers of studies | Studies with improvement in olfactory measurement (# of studies/total) | Statistically significant benefit (# of studies/total) |
|--------------|--------------------|-------------------------------------------------|--------------------------------------------------|
| ESS          | 2                  | 2/2                                             | 1/2                                              |
| ASA          | 7                  | 6/7                                             | 5/7                                              |
| Monoclonal antibodies | 5                  | 5/5                                             | 4/5                                              |
| ESS + ASA    | 3                  | 3/3                                             | 2/3⁴²                                            |

⁴² Study by Fruth et al⁴² did not demonstrate statistically significant benefit but utilized 100 mg ASA daily, lower than the currently recommended 325–1300 mg daily dosage.

**AERD and olfaction**

Olfactory dysfunction is a widely recognized component of chronic rhinosinusitis (CRS) with 78% of patients suffering from diminished or absent sense of smell. Diagnosis is established with ASA challenge testing. Over time, patients develop nasal polyposis, nasal obstruction, and hyposmia. The sinonasal symptoms associated with AERD are often severe and prompt patients to seek intervention. As compared to their counterparts with ASA-tolerant chronic rhinosinusitis, patients with AERD tend to have recalcitrant disease, requiring more frequent and revision sinus surgery with higher rates of healthcare utilization. Unfortunately, these patients also have poorer outcomes after endoscopic sinus surgery (ESS) as measured by symptom metrics and endoscopic findings. Nevertheless, ESS has still proven to be a critical treatment modality with sustained clinical improvement after long term follow-up, despite the higher likelihood for revision surgery.
symptoms and decreased sense of smell contribute most to patients’ decrease in QOL. Although olfaction is included in most metrics of sinonasal disease, it is not necessarily correlated with improvements in other symptom domains, such as nasal obstruction or rhinorrhea. Patients with AERD are also at higher risk of impaired eating related QOL because of the interplay between olfactory dysfunction and taste. Despite the known effect of hyposmia on patients’ quality of life, many publications do not explicitly track olfactory outcomes following treatment. This paper aims to review the available data on the effects of various treatment modalities on olfaction in patients with AERD.

Methods of measurement

Before evaluating the olfactory outcomes, it is important to understand the various metrics that are used in clinical practice and research. The available diagnostic tools can be divided into two categories: subjective patient reported outcome metrics (PROMs) and objective tests of the olfactory system.

Patient reported outcome measures

The most common PROM is a component of the Sinonasal Outcome Test-22 (SNOT-22), which contains a question asking patients to rate the severity of their limitation in smell and taste. This metric uses a Likert scale from 0 to 5 where 0 is “no problem” and 5 is that the “problem is as bad as it can be.” The SNOT-22 questionnaire has been used extensively to measure outcomes in chronic rhinosinusitis. However, there are 15 different patient reported outcome metrics that have been validated for use in CRS. Visual analog scales are also used as standalone questions in some studies or as a component of a validated metric, such as the Rhinosinusitis Task Force symptom score. Some studies dichotomize this question into normal olfaction versus impaired sense of smell, while others use a categorical variable classifying olfaction as normal, diminished, or absent.

While PROMs are much easier to administer, it is important to understand their limitations. An interesting study by Landis et al demonstrates that healthy subjects are unable to accurately self-report their sense of smell. However, the accuracy of this self-assessment improves after undergoing olfactory testing, forcing them to pay conscious attention to their sense of smell. Fortunately, in patients with sinonasal disease, the sensitivity of self-reported olfactory impairment is much higher, greater than 90% in multiple studies. However, the specificity of this question is lower, such that patients with sinonasal disease overstate their diminished sense of smell, which may explain CRS patients’ tendency to overestimate their extent of olfactory impairment.

Objective olfactory assessments

The University of Pennsylvania Smell Identification Test (UPSIT) assesses an individual’s ability to identify 40 odors and has a high retest reliability, $r = 0.9$. Scores range from 0 to 40, corresponding to the number of correctly identified odors. The advantage of the forced-choice nature of this assessment allows for potential detection of malingering, which is suggested by a score $<10$, which would be achieved by someone with complete anosmia that is randomly guessing.

In an effort to make olfactory testing more widely available and easier to use, two modifications of the UPSIT were developed, known as the Connecticut Chemosensory Clinical Research Center (CCCRC) test and the Cross-Cultural Smell Identification Test (CC-SIT). The CCCRC test assesses odor identification of 10 scents and olfactory threshold; $r = 0.77$. The CC-SIT was designed as the most rapid test and assesses only odor identification of 12 scents with a retest reliability of $r = 0.71$.

“Sniffin’ Sticks” is an olfactory test that has also been widely used and validated in patients with CRS. Sniffin Sticks can be used to test olfactory thresholds, odor discrimination, or odor identification. Often, a combination assessment of these three domains is used, called the TDI score (range: 1–48). A TDI score $\leq 15$ signifies anosmia, $\leq 30$ signifies hyposmia, and $>30$ is seen in normal participants. The retest reliability for the composite assessment is $r = 0.72$.

Outcomes

Endoscopic sinus surgery

Of the many studies that evaluate ESS in patients with AERD (Table 1), only two report olfactory outcomes of ESS without associated ASA desensitization—all utilizing PROMs. Mendelsohn et al demonstrate a significant decrease in olfactory dysfunction following ESS: 92% preoperatively compared with 59% postoperatively. In a case series, Young et al demonstrate a decrease in patient reported olfactory dysfunction 24 months after ESS, but this trended back towards preoperative anosmia levels 3 years postoperatively.

Aspirin desensitization therapy

All seven studies that evaluate olfactory outcomes following ASA desensitization demonstrated improvements in patient reported and objective assessments of olfactory function with six out of seven studies reporting statistical significance (Table 2). The dosage of ASA used ranged from 40.5 mg daily to 650 mg BID. One study by Rozsasi et al directly compared two dosages of ASA (100 vs. 300 mg) and demonstrated a significant improvement in olfaction only in the group receiving 300 mg daily. In one of the earliest landmark studies, Sweet et al studied outcomes in individuals who were on long term ASA therapy and those who discontinued therapy for a variety of reasons. Patient reported outcomes demonstrate statistically significant improvement while on ASA with a subsequent worsening of symptoms after discontinuation.

Biologic agents — monoclonal antibodies

Three biologic agents are currently used in the management of AERD. Omalizumab, initially developed for the
management of severe asthma has also been demonstrated to improve desensitization rates in those who previously failed ASA therapy due to adverse reaction. Hayashi et al demonstrate a statistically significant decrease in patient reported olfactory dysfunction after 1 year of treatment with omalizumab (8.8 → 3.0).38 Two additional case series also demonstrate improvement in patient reported olfaction, which did not reach statistical significance.36,37

Mepolizumab, an anti-IL-5 human monoclonal antibody, was studied in 14 patients with AERD. Patients reported a statistically significant improvement in the smell/taste subscore of the SNOT-22 questionnaire (4 → 3) following treatment.39

Most recently, Liadlaw et al published results from a subset of patients with AERD participating in a larger trial evaluating the effectiveness of Dupilumab, an anti-IL-4 and IL-13 human monoclonal antibody, in the management of CRSwNP. Patients exhibited a >50% improvement in olfactory dysfunction as measured by the UPSIT and SNOT-22 assessments (p < .005).35

Combination therapy: ESS + ASA

Three studies report olfactory outcomes following combination ESS with subsequent ASA desensitization (500 mg daily). Havel et al demonstrated statistically significant reductions in patient reported olfactory dysfunction after ESS and ASA desensitization. The same effect was not observed in the control group, who received ESS without subsequent ASA desensitization.40 Similar outcomes are noted in a case series by Cho et al with a statistically significant decrease in SNOT-22 smell subscore postoperatively that is maintained with ASA desensitization.41 Fruth et al performed a double blinded placebo-controlled cohort study comparing ESS + low dose ASA desensitization (100 mg daily) to ESS + placebo. While the experimental group exhibited an improvement in odor identification of Sniffin’ Sticks, statistical significance was not achieved.42

Conclusion

Olfactory dysfunction has a major negative impact on the QOL of patients with AERD. In patients with AERD, improvements in other sinonasal symptoms may not be correlated with improvement in sense of smell. There is considerable evidence that each of the reviewed therapies (ESS, ASA desensitization, and monoclonal antibodies) improves olfaction in patients with AERD. It is difficult to directly compare the results of these studies because of heterogeneity in patient populations and treatment algorithms, which make performing a meta-analysis challenging. The available data is suggestive of improved long term olfactory outcomes with multi-modality therapy, specifically ESS + ASA desensitization. To the authors’ knowledge there are no studies to date that investigate synergistic effects and olfactory outcomes of monoclonal antibodies with aspirin desensitization or surgical therapy. Additional research using objective outcome measures is needed to demonstrate which therapies offer the most improvement in olfactory dysfunction, a facet of AERD that significantly contributes to worsened QOL. Clinicians and researchers should pay specific attention to olfactory symptoms in patients with AERD.

Funding

None.

Declaration of competing interest

None.

References

1. Widal F, Abrami P, Lermoyez J. First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria) — 1922 (with a note on aspirin desensitization). J Lermoyez J Asthma. 1987;24:297—300.
2. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968;68: 975–983.
3. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135:676–681.e1.
4. Bosso JV, Schwartz LB, Stevenson DD. Tryptase and histamine release during aspirin-induced respiratory reactions. J Allergy Clin Immunol. 1991;88:830–837.
5. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D₂ as a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135:245–252.
6. Amar YG, Frenkiel S, Sobol SE. Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter’s triad. J Laryngology. 2000;29:7–12.
7. Mendelsohn D, Jeremic G, Wright ED, Rotenberg BW. Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol. 2011;120:162–166.
8. Benninger MS, Holy CE. The impact of endoscopic sinus surgery on health care use in patients with respiratory comorbidities. Otolaryngol Head Neck Surg. 2014;151:508–515.
9. Smith TL, Mendolia-Loffredo S, Loehr TA, Sparapani R, Laud PW, Nattinger AB. Predictive factors and outcomes in endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope. 2005;115:2199–2205.
10. Young J, Frenkiel S, Tewfik MA, Mouadeb DA. Long-term outcome analysis of endoscopic sinus surgery for chronic sinusitis. Am J Rhinol. 2007;21:743–747.
11. Robinson JL, Griest S, James KE, Smith TL. Impact of aspirin intolerance on outcomes of sinus surgery. Laryngoscope. 2007; 117:825–830.
12. Jang DW, Comer BT, Lachanas VA, Kountakis SE. Aspirin sensitivity does not compromise quality-of-life outcomes in patients with samter’s triad. Laryngoscope. 2014;124:34–37.
13. Kohli P, Naik AN, Harruff EE, Nguyen SA, Schlosser RJ, Soler ZM. The prevalence of olfactory dysfunction in chronic rhinosinusitis. Laryngoscope. 2017;127:309–320.
14. Kern RC. Chronic sinusitis and anosmia: pathologic changes in the olfactory mucosa. Laryngoscope. 2000;110:1071–1077.
15. Gudziol V, Michel M, Sonnefeld C, Koschel D, Hummel T. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. Eur Arch Otorhinolaryngol. 2017;274:1487–1493.
16. Morse JC, Shills MH, Ely KA, et al. Patterns of olfactory dysfunction in chronic rhinosinusitis identified by hierarchical
cluster analysis and machine learning algorithms. Int Forum Allergy Rhinol. 2019;9:255–264.

17. Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3:711–718.

18. Rowan NR, Soler ZM, Storck KA, et al. Impaired eating-related quality of life in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;9:240–247.

19. Rudnik L, Hopkins C, Peters A, Smith TL, Schlosser RJ, Soler ZM. Patient-reported outcome measures for adult chronic rhinosinusitis: a systematic review and quality assessment. J Allergy Clin Immunol. 2015;136:1532–1540.e2.

20. Landis BN, Hummel T, Hugentobler M, Giger R, Lacroix JS. Ratings of overall olfactory function. Chem Senses. 2003;28:691–694.

21. Gent JF, Goodspeed RB, Zagranis RT, Catalanotto FA. Taste and smell problems: validation of questions for the clinical history. Yale J Biol Med. 1987;60:27–35.

22. Nordin S, Monsch AU, Murphy C. Unawareness of smell loss in normal aging and Alzheimer’s disease: discrepancy between self-reported and diagnosed smell sensitivity. J Gerontol B Psychol Sci Soc Sci. 1995;50:P187–P192.

23. Doty RL, Dann SM. Development of the university of Pennsylvania smell identification test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32:489–502.

24. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope. 1984;94:176–178.

25. Cain WS, Gent JF, Goodspeed RB, Leonard G. Evaluation of olfactory dysfunction in the connecticut chemosensory clinical research center. Laryngoscope. 1988;98:83–88.

26. Doty RL, Marcus A, Lee WW. Development of the 12-item cross-cultural smell identification test (CC-SIT). Laryngoscope. 1996;106:353–356.

27. Klimek L, Dollner R, Pfaar O, Mullol J. Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)? Curr Allergy Asthma Rep. 2014;14:441.

28. Hummel T, Kobal G, Guzdiol H, Mackay-Sim A. Normative data for the "Sniffin Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3000 subjects. Eur Arch Otorhinolaryngol. 2007;264:237–243.

29. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22:39–52.

30. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180–186.

31. Walters KM, Waldram JD, Woessner KM, White AA. Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2018;32:280–286.

32. Swierczyńska-Krepa M, Sanak M, Bochenek G, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014;134:883–890.

33. Sweet JM, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization – treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol. 1990;85:59–65.

34. Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008;63:1228–1234.

35. Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract. 2019;7:2462–2465.

36. Phillips-Angles E, Barranco P, Lluch-Bernal M, Dominguez-Ortega J, Lopez-Carrasco V, Quirce S. Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab. J Allergy Clin Immunol Pract. 2017:5:842–845.

37. Tiotiu A, Oster J, Roux P, et al. Omalizumab’s effectiveness in severe allergic asthma and nasal polyps: a real-life study. J Invest Allerg Clin Immunol. 2019;30.

38. Hayashi H, Mitsu C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1585–1587.e4.

39. Tuttle KL, Buchheit KM, Laidlaw TM, Cahill KN. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2018;6:1045–1047.

40. Havel M, Erö L, Braunischweig F, et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol. 2013;270:571–578.

41. Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151:575–581.

42. Fruth K, Pogorzelski B, Schmidtman I, et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy. 2013;68:659–665.